Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies.

Andrew Young1

  • 1Amylin Pharmaceuticals, Inc., San Diego, California, USA.

Advances in Pharmacology (San Diego, Calif.)
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Amylin/insulin co-replacement therapy using pramlintide acetate improves glucose control in type 1 and type 2 diabetes. This therapy, while effective, requires careful insulin dose adjustment to mitigate hypoglycemia risks, especially initially.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remote sensing data and machine learning models estimate sorghum grain yield in a plant breeding program.

Plant phenomics (Washington, D.C.)·2026
Same author

Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial.

Vaccine·2026
Same author

Stepwise loss of complexity in hagfish eyes prior to deep sea colonization.

Biology letters·2026
Same author

Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state.

Communications biology·2026
Same author

Physiological and Yield Responses of Peanut (<i>Arachis hypogaea</i> L.) Genotypes Under Well-Watered and Water-Stressed Conditions.

Plants (Basel, Switzerland)·2026
Same author

Nerve Combing for Idiopathic Trigeminal Neuralgia Without Neurovascular Compression.

Journal of clinical and experimental dentistry·2026
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 1 diabetes involves both insulin and amylin deficiency.
  • Early therapeutic concepts proposed amylin/insulin co-replacement therapy for improved glucose management.

Purpose of the Study:

  • To evaluate the efficacy and safety of pramlintide acetate, an amylinomimetic, as an adjunct to insulin therapy.
  • To assess the impact of co-therapy on glycemic control, body weight, and hypoglycemia risk.

Main Methods:

  • Clinical trials involving patients with type 1 and type 2 diabetes treated with pramlintide acetate and insulin.
  • Monitoring of glycemic parameters (HbA1c), body weight, insulin dose, and adverse events, including hypoglycemia.

Main Results:

Related Experiment Videos

  • Pramlintide acetate co-therapy led to a sustained decrease in HbA1c (0.4-0.5%) compared to placebo.
  • Associated with reduced body weight and insulin requirements.
  • Increased risk of hypoglycemia, particularly at therapy initiation, manageable with pre-emptive insulin dose reduction.

Conclusions:

  • Pramlintide acetate is an effective first-in-class amylinomimetic for improving glycemic control in diabetes.
  • Co-therapy demonstrates benefits beyond insulin alone, with manageable side effects and risks.
  • Replication of animal study findings in humans, including slowed gastric emptying and reduced food intake.